Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries.

Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries. Experts suggest the value of DCTs will increase by 9.8% between 2023 to 2029. Decentralized Clinical trials are cost effective and offer many benefits to researchers and participants alike, which is likely the cause of their increased usage. However, there are also some risks involved. To address this, the FDA released draft guidance to regulate DCTs and ensure participant privacy and data is protected. The guidance covers data collection and storage, investigator and sponsor responsibilities, and more.